Table 5 Accelerated-failure time model
Factor | Time ratio univariate | 95% CI | Time ratio multivariate | 95% CI | P -value |
|---|---|---|---|---|---|
Cohort | |||||
Cohort(73–82) | 1.00 | 1.00 | |||
Cohort(83–92) | 4.85*** | 1.93, 12.22 | 1.92* | 1.02, 3.62 | 0.045 |
Cohort(93–02) | 22.58*** | 8.84, 57.71 | 4.60*** | 2.28, 9.30 | <0.001 |
Age group | |||||
Age gp (<26) | 1.00 | 1.00 | |||
Age gp(26–45) | 0.64 | 0.26, 1.57 | 0.81 | 0.39, 1.66 | 0.556 |
Age gp(46–65) | 0.07*** | 0.03, 0.18 | 0.14*** | 0.06, 0.30 | <0.001 |
Age gp(66+) | 0.004*** | 0.001, 0.011 | 0.02*** | 0.01, 0.06 | <0.001 |
Gender | |||||
Male | 1.00 | 1.00 | 0.85, 2.51 | ||
Female | 1.26 | 0.51, 3.13 | 1.46 | 0.85, 2.51 | 0.170 |
Treatment | |||||
Chemotherapy | 1.00 | 1.00 | |||
Combi (chemo+radio) | 23.22*** | 9.36, 57.65 | 2.06 | 0.99, 4.28 | 0.053 |
Radiotherapy | 27.14*** | 11.83, 62.28 | 2.63* | 1.24, 5.57 | 0.011 |
B symptom | |||||
No | 1.00 | 1.00 | |||
Yes | 0.39* | 0.17, 0.91 | 0.42** | 0.23, 0.76 | 0.005 |
Who | |||||
Lymphocyte | 1.00 | 1.00 | |||
Mixed Cell | 0.22* | 0.06, 0.88 | 0.31* | 0.11, 0.85 | 0.022 |
Nodular Scl | 0.49 | 0.14, 1.75 | 0.37* | 0.15, 0.92 | 0.032 |
Unspecified | 0.001*** | 0.0003, 0.008 | 0.03*** | 0.01, 0.14 | <0.001 |
Stages | |||||
Stage I | 1.00 | 1.00 | |||
Stage II | 0.33* | 0.13, 0.83 | 0.37* | 0.16, 0.84 | 0.018 |
Stage III | 0.06*** | 0.02, 0.15 | 0.29** | 0.12, 0.68 | 0.005 |
Stage IV | 0.02*** | 0.006, 0.089 | 0.22** | 0.08, 0.63 | 0.005 |
Stage V | 0.001*** | 0.0004, 0.004 | 0.06*** | 0.01, 0.26 | <0.001 |
